LCTX 1.22 ▲ 1.67% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Lineage Cell Therapeutics...

    AMEX: LCTX · Real-Time Price · USD
    1.22
    0.02 (1.67%)
    At close: Sep 05, 2025, 3:59 PM
    1.23
    0.82%
    Pre-market: Sep 08, 2025, 04:44 AM EDT
    1.67%
    Bid 1.17
    Market Cap 278.59M
    Revenue (ttm) 10.91M
    Net Income (ttm) -40.91M
    EPS (ttm) -0.17
    PE Ratio (ttm) -7.18
    Forward PE -17.29
    Analyst Buy
    Ask 1.24
    Volume 699,685
    Avg. Volume (20D) 2,526,775
    Open 1.20
    Previous Close 1.20
    Day's Range 1.19 - 1.23
    52-Week Range 0.37 - 1.31
    Beta 1.67

    About LCTX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol LCTX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for LCTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Lineage Cell Therapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    9 months ago
    -28.99%
    Lineage Cell Therapeutics shares are trading lower... Unlock content with Pro Subscription
    news image

    6 days ago · businesswire.com

    Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

    CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...

    news image

    3 weeks ago · seekingalpha.com

    Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript

    Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian M. Culley - CEO, President & Director Ioana C.

    news image

    3 weeks ago · zacks.com

    Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

    Lineage Cell (LCTX) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.

    news image

    1 month ago · businesswire.com

    Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

    CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell ...

    news image

    1 month ago · businesswire.com

    Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

    CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...

    news image

    2 months ago · businesswire.com

    OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

    CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...

    news image

    2 months ago · https://www.defenseworld.net

    Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

    Squarepoint Ops LLC acquired a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) during the 4th quarter, according to the company in its most recent filing with the ...

    Add to Watchlist